An Overview of Nanotechnological Approaches for the Diagnosis and
Treatment of Allergic Illness

Bhupendra      Sharma; Rohitas      Deshmukh
doi:10.2174/1381612829666230828104015
Abstract

Allergies are a major health issue. Allergen avoidance, antihistamines, and corticosteroids do not treat the pathology's causes, therefore long-term therapy is essential. Long-term allergen-specific immunotherapy builds immune tolerance to the allergen. Unfortunately, immunotherapies for all allergens are not available, and adverse reactions during therapy, especially in severely allergic persons, remain a worry. In this regard, cell and bio- or nanomaterial-based allergy treatments are promising. This overview covers the most important tactics from these two strategies with examples. Nanotechnology encompasses science, engineering, and technology at 1-100 nm. Due to their one-of-a-kind characteristics, nanomaterials can be used in healthcare. Small molecules' chemical and physical properties are modified by the system's size, shape, content, and function. Toxicity and hypersensitivity reactions need to be evaluated. Regulating the physico-chemical properties of numerous accessible structures would make clinical diagnosis and therapy safer and more successful. Dendrimeric antigens, nanoallergens, and nanoparticles can mimic carrier proteins, boost specific IgE binding, and improve signal detection in allergy diagnosis. In immunotherapy, several allergenic structures like glycodendrimers, liposomes, polymers, and nanoparticles have been used as adjuvants, protectors, or depots for allergens. Nanotechnology has the potential to substantially improve both the diagnosis and treatment of allergies.
« Previous Next »
[1]
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol  2015; 16(1): 45-56.
 [http://dx.doi.org/10.1038/ni.3049] [PMID: 25521684]

[2]
Ozdemir C, Akdis M, Akdis CA. T-cell response to allergens. Chem Immunol Allergy  2010; 95: 22-44.
 [http://dx.doi.org/10.1159/000315936] [PMID: 20519880]

[3]
Méndez-Enríquez E, Hallgren J. Mast cells and their progenitors in allergic asthma. Front Immunol  2019; 10: 821.
 [http://dx.doi.org/10.3389/fimmu.2019.00821] [PMID: 31191511]

[4]
Muraro A. The european academy of allergy and clinical immunology (eaaci) advocacy manifesto tackling the allergy crisis in Europe-Concerted Policy Action Needed. Brussels, Belgium: EAACI-EU Liaison Office 2015.

[5]
Komlósi ZI, Kovács N, Sokolowska M, van de Veen W, Akdis M, Akdis CA. Mechanisms of subcutaneous and sublingual aeroallergen immunotherapy. Immunol Allergy Clin North Am  2020; 40(1): 1-14.
 [http://dx.doi.org/10.1016/j.iac.2019.09.009] [PMID: 31761112]

[6]
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano  2009; 3(1): 16-20.
 [http://dx.doi.org/10.1021/nn900002m] [PMID: 19206243]

[7]
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer  2017; 17(1): 20-37.
 [http://dx.doi.org/10.1038/nrc.2016.108] [PMID: 27834398]

[8]
Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev  2011; 63(3): 136-51.
 [http://dx.doi.org/10.1016/j.addr.2010.04.009] [PMID: 20441782]

[9]
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res  1986; 46(12 Pt 1): 6387-92.
 [PMID: 2946403]

[10]
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev  2014; 66: 2-25.
 [http://dx.doi.org/10.1016/j.addr.2013.11.009] [PMID: 24270007]

[11]
Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours. Nat Mater  2020; 19(5): 566-75.
 [http://dx.doi.org/10.1038/s41563-019-0566-2] [PMID: 31932672]

[12]
Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS Nano  2015; 9(1): 16-30.
 [http://dx.doi.org/10.1021/nn5062029] [PMID: 25469470]

[13]
Feng X, Liu J, Xu W, Li G, Ding J. Tackling autoimmunity with nanomedicines. Nanomedicine  2020; 15(16): 1585-97.
 [http://dx.doi.org/10.2217/nnm-2020-0102] [PMID: 32669025]

[14]
Paris JL, Baeza A. Nano- and microscale drug delivery approaches for therapeutic immunomodulation. ChemNanoMat  2021; 7(7): 773-88.
 [http://dx.doi.org/10.1002/cnma.202100062]

[15]
Fontana F, Figueiredo P, Bauleth-Ramos T, Correia A, Santos HA. Immunostimulation and immunosuppression: Nanotechnology on the brink. Small Methods  2018; 2(5): 1700347.
 [http://dx.doi.org/10.1002/smtd.201700347]

[16]
Wong A, Seger DL, Lai KH, Goss FR, Blumenthal KG, Zhou L. Drug hypersensitivity reactions documented in electronic health records within a large health system. J Allergy Clin Immunol Pract  2019; 7(4): 1253-1260.e3.
 [http://dx.doi.org/10.1016/j.jaip.2018.11.023] [PMID: 30513361]

[17]
Pouessel G, Beaudouin E, Tanno LK, et al. Food-related anaphylaxis fatalities: Analysis of the allergy vigilance network® database. Allergy  2019; 74(6): 1193-6.
 [http://dx.doi.org/10.1111/all.13717] [PMID: 30636053]

[18]
Flores Kim J, McCleary N, Nwaru BI, Stoddart A, Sheikh A. Diagnostic accuracy, risk assessment, and cost-effectiveness of component-resolved diagnostics for food allergy: A systematic review. Allergy  2018; 73(8): 1609-21.
 [http://dx.doi.org/10.1111/all.13399] [PMID: 29319184]

[19]
Eguiluz-Gracia I, Tay TR, Hew M, et al. Recent developments and highlights in biomarkers in allergic diseases and asthma. Allergy  2018; 73(12): 2290-305.
 [http://dx.doi.org/10.1111/all.13628] [PMID: 30289997]

[20]
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy  2019; 74(1): 14-27.
 [http://dx.doi.org/10.1111/all.13562] [PMID: 30028512]

[21]
Pohlit H, Bellinghausen I, Frey H, Saloga J. Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy  2017; 72(10): 1461-74.
 [http://dx.doi.org/10.1111/all.13199] [PMID: 28474379]

[22]
Feynman RP. There’s plenty of room at the bottom. An invitation to enter a new field of physics. Eng Sci  1960; XXIII(5): 22-36.

[23]
Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The History of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules  2019; 25(1): 112.
 [http://dx.doi.org/10.3390/molecules25010112] [PMID: 31892180]

[24]
Khalid K, Tan X, Mohd Zaid HF, et al. Advanced in developmental organic and inorganic nanomaterial: A review. Bioengineered  2020; 11(1): 328-55.
 [http://dx.doi.org/10.1080/21655979.2020.1736240] [PMID: 32138595]

[25]
Maurya A, Singh AK, Mishra G, et al. Strategic use of nanotechnology in drug targeting and its consequences on human health: A focused review. Interv Med Appl Sci  2019; 11(1): 38-54.
 [http://dx.doi.org/10.1556/1646.11.2019.04] [PMID: 32148902]

[26]
Breiteneder H, Diamant Z, Eiwegger T, et al. Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. Allergy  2019; 74(12): 2293-311.
 [http://dx.doi.org/10.1111/all.13851] [PMID: 31056763]

[27]
Yeo ISL. Modifications of dental implant surfaces at the microand nano-level for enhanced osseointegration. Materials  2019; 13(1): 89.
 [http://dx.doi.org/10.3390/ma13010089] [PMID: 31878016]

[28]
Hao Y, Zhou X, Li R, Song Z, Min Y. Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2020; 12(2): e1574.
 [http://dx.doi.org/10.1002/wnan.1574] [PMID: 31566896]

[29]
Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A. Nanomedicines to deliver mRNA: State of the art and future perspectives. Nanomaterials  2020; 10(2): 364.
 [http://dx.doi.org/10.3390/nano10020364] [PMID: 32093140]

[30]
Paradise J. Regulating nanomedicine at the food and drug administration. AMA J Ethics  2019; 21(4): E347-55.
 [http://dx.doi.org/10.1001/amajethics.2019.347] [PMID: 31012422]

[31]
Chapman MD, Wuenschmann S, King E, Pomés A. Technological innovations for high-throughput approaches to in vitro allergy diagnosis. Curr Allergy Asthma Rep  2015; 15(7): 36.
 [http://dx.doi.org/10.1007/s11882-015-0539-8] [PMID: 26143391]

[32]
Mayorga C, Perez-Inestrosa E, Molina N, Montañez MI. Development of nanostructures in the diagnosis of drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol  2016; 16(4): 300-7.
 [http://dx.doi.org/10.1097/ACI.0000000000000282] [PMID: 27257940]

[33]
Zubeldia JM, Ferrer M, Dávila I, Justicia JL. Adjuvants in allergenspecific immunotherapy: Modulating and enhancing the immune response. J Investig Allergol Clin Immunol  2019; 29(2): 103-11.
 [http://dx.doi.org/10.18176/jiaci.0349] [PMID: 30418155]

[34]
Johnson L, Duschl A, Himly M. Nanotechnology-based vaccines for allergen-specific immunotherapy: Potentials and challenges of conventional and novel adjuvants under research. Vaccines  2020; 8(2): 237.
 [http://dx.doi.org/10.3390/vaccines8020237] [PMID: 32443671]

[35]
Mayorga C, Fernandez TD, Montañez MI, Moreno E, Torres MJ. Recent developments and highlights in drug hypersensitivity. Allergy  2019; 74(12): 2368-81.
 [http://dx.doi.org/10.1111/all.14061] [PMID: 31557314]

[36]
Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy  2019; 74(8): all.13765.
 [http://dx.doi.org/10.1111/all.13765] [PMID: 30843233]

[37]
Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: An EAACI position paper. Allergy  2019; 74(10): 1835-51.
 [http://dx.doi.org/10.1111/all.13806] [PMID: 30953574]

[38]
Ansotegui IJ, Melioli G, Canonica GW, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. W Allergy Organ J  2020; 13(2): 100080.
 [http://dx.doi.org/10.1016/j.waojou.2019.100080] [PMID: 32128023]

[39]
Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: An ENDA/EAACI Drug Allergy Interest Group position paper. Allergy  2016; 71(8): 1103-34.
 [http://dx.doi.org/10.1111/all.12886] [PMID: 26991315]

[40]
Ariza A, Mayorga C, Salas M, et al. The influence of the carrier molecule on amoxicillin recognition by specific IgE in patients with immediate hypersensitivity reactions to betalactams. Sci Rep  2016; 6(1): 35113.
 [http://dx.doi.org/10.1038/srep35113] [PMID: 27731424]

[41]
Barbero N, Fernández-Santamaría R, Mayorga C, et al. Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions. Allergy  2019; 74(8): all.13761.
 [http://dx.doi.org/10.1111/all.13761] [PMID: 30829415]

[42]
Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy  2015; 70(11): 1393-405.
 [http://dx.doi.org/10.1111/all.12698] [PMID: 26198455]

[43]
Hamilton RG, Franklin Adkinson N Jr. In vitro assays for the diagnosis of IgE-mediated disorders. J Allergy Clin Immunol  2004; 114(2): 213-25.
 [http://dx.doi.org/10.1016/j.jaci.2004.06.046] [PMID: 15316492]

[44]
Märki I, Rebeaud F. Nanotechnologies for in vitro IgE testing. Curr Allergy Asthma Rep  2017; 17(7): 50.
 [http://dx.doi.org/10.1007/s11882-017-0717-y] [PMID: 28623535]

[45]
Lupinek C, Wollmann E, Baar A, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: The MeDALL allergen-chip. Methods  2014; 66(1): 106-19.
 [http://dx.doi.org/10.1016/j.ymeth.2013.10.008] [PMID: 24161540]

[46]
Matricardi PM, Kleine-Tebbe J. Molecular allergology between precision medicine and the choosing wisely initiative. Clin Exp Allergy  2016; 46(5): 664-7.
 [http://dx.doi.org/10.1111/cea.12679] [PMID: 27112118]

[47]
Faber M, Sabato V, Witte L, et al. State of the art and perspectives in food allergy (part I): Diagnosis. Curr Pharm Des  2014; 20(6): 954-63.
 [http://dx.doi.org/10.2174/13816128113199990046] [PMID: 23701559]

[48]
Mayorga C, Gomez F, Aranda A, et al. Basophil response to peanut allergens in mediterranean peanut-allergic patients. Allergy  2014; 69(7): 964-8.
 [http://dx.doi.org/10.1111/all.12421] [PMID: 24816395]

[49]
Laguna JJ, Bogas G, Salas M. The basophil activation test can be of value for diagnosing immediate allergic reactions to omeprazole. J Allergy Clin Immunol Pract  2018; 6(5): 1628-36.
 [http://dx.doi.org/10.1016/j.jaip.2017.12.001] [PMID: 29339127]

[50]
Salas M, Fernández-Santamaría R, Mayorga C, et al. Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy. J Allergy Clin Immunol Pract  2018; 6(3): 1010-1018.e2.
 [http://dx.doi.org/10.1016/j.jaip.2017.08.009] [PMID: 28964705]

[51]
Doña I, Torres MJ, Montañez MI, Fernández TD. In vitro diagnostic testing for antibiotic allergy. Allergy Asthma Immunol Res  2017; 9(4): 288-98.
 [http://dx.doi.org/10.4168/aair.2017.9.4.288] [PMID: 28497915]

[52]
Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: Similarities and differences between Europe and North America. Clin Transl Allergy  2017; 7(1): 7.
 [http://dx.doi.org/10.1186/s13601-017-0144-0] [PMID: 28293415]

[53]
Sánchez-Sancho F, Pérez-Inestrosa E, Suau R, Mayorga C, Torres MJ, Blanca M. Dendrimers as carrier protein mimetics for IgE antibody recognition. Synthesis and characterization of densely penicilloylated dendrimers. Bioconjug Chem  2002; 13(3): 647-53.
 [http://dx.doi.org/10.1021/bc0155824] [PMID: 12009957]

[54]
Ruiz-Sanchez AJ, Montañez MI, Mayorga C, et al. Dendrimer- modified solid supports: Nanostructured materials with potential drug allergy diagnostic applications. Curr Med Chem  2012; 19(29): 4942-54.
 [http://dx.doi.org/10.2174/0929867311209024942] [PMID: 22963628]

[55]
Montañez MI, Najera F, Mayorga C, et al. Recognition of multiepitope dendrimeric antigens by human immunoglobulin E. Nanomedicine  2015; 11(3): 579-88.
 [http://dx.doi.org/10.1016/j.nano.2015.01.006] [PMID: 25661921]

[56]
Maharjan RS, Singh AV, Hanif J, et al. Investigation of the associations between a nanomaterial’s microrheology and toxicology. ACS Omega  2022; 7(16): 13985-97.
 [http://dx.doi.org/10.1021/acsomega.2c00472] [PMID: 35559161]

[57]
Vida Y, Montañez MI, Collado D, et al. Dendrimeric antigen-silica particle composites: An innovative approach for IgE quantification. J Mater Chem B Mater Biol Med  2013; 1(24): 3044-50.
 [http://dx.doi.org/10.1039/c3tb20548g] [PMID: 32261007]

[58]
Soler M, Mesa-Antunez P, Estevez MC, et al. Highly sensitive dendrimer-based nanoplasmonic biosensor for drug allergy diagnosis. Biosens Bioelectron  2015; 66: 115-23.
 [http://dx.doi.org/10.1016/j.bios.2014.10.081] [PMID: 25460891]

[59]
Ashraf S, Qadri S, al-Ramadi B, Haik Y. Nanoparticles rapidly assess specific IgE in plasma. Nanotechnology  2012; 23(30): 305101.
 [http://dx.doi.org/10.1088/0957-4484/23/30/305101] [PMID: 22782087]

[60]
Teste B, Malloggi F, Siaugue JM, Varenne A, Kanoufi F, Descroix S. Microchip integrating magnetic nanoparticles for allergy diagnosis. Lab Chip  2011; 11(24): 4207-13.
 [http://dx.doi.org/10.1039/c1lc20809h] [PMID: 22033539]

[61]
Wang J, Munir A, Li Z, Zhou HS. Aptamer–Au NPs conjugates-enhanced SPR sensing for the ultrasensitive sandwich immunoassay. Biosens Bioelectron  2009; 25(1): 124-9.
 [http://dx.doi.org/10.1016/j.bios.2009.06.016] [PMID: 19592231]

[62]
Wang Y, Cui M, Jiao M, Luo X. Antifouling and ultrasensitive biosensing interface based on self-assembled peptide and aptamer on macroporous gold for electrochemical detection of immunoglobulin E in serum. Anal Bioanal Chem  2018; 410(23): 5871-8.
 [http://dx.doi.org/10.1007/s00216-018-1201-9] [PMID: 29938372]

[63]
Platt GW, Damin F, Swann MJ, et al. Allergen immobilisation and signal amplification by quantum dots for use in a biosensor assay of IgE in serum. Biosens Bioelectron  2014; 52: 82-8.
 [http://dx.doi.org/10.1016/j.bios.2013.08.019] [PMID: 24028905]

[64]
Bojcukova J, Vlas T, Forstenlechner P, Panzner P. Comparison of two multiplex arrays in the diagnostics of allergy. Clin Transl Allergy  2019; 9(1): 31.
 [http://dx.doi.org/10.1186/s13601-019-0270-y]

[65]
Heffler E, Puggioni F, Peveri S, Montagni M, Canonica GW, Melioli G. Extended IgE profile based on an allergen macroarray: A novel tool for precision medicine in allergy diagnosis. World Allergy Organ J  2018; 11(1): 7.
 [http://dx.doi.org/10.1186/s40413-018-0186-3] [PMID: 29743964]

[66]
Mari A, Alessandri C, Giangrieco I, et al. Introducing FABER test for allergy diagnosis: Food molecule- and extract-based allergenic preparations in the newest and broadest nanotechnology IgE test. Clin Transl Allergy  2017; 7(S1): OP11.

[67]
Deak PE, Kim B, Adnan A. Nanoallergen platform for detection of platin drug allergies. J Allergy Clin Immunol  2019; 143(5): 1957-60.
 [http://dx.doi.org/10.1016/j.jaci.2019.01.010] [PMID: 30682456]

[68]
Molina N, Martin-Serrano A, Fernandez T, et al. Dendrimeric antigens for drug allergy diagnosis: A new approach for basophil activation tests. Molecules  2018; 23(5): 997.
 [http://dx.doi.org/10.3390/molecules23050997] [PMID: 29695102]

[69]
Gómez-Arribas L, Benito-Peña E, Hurtado-Sánchez M, Moreno-Bondi M. Biosensing based on nanoparticles for food allergens detection. Sensors  2018; 18(4): 1087.
 [http://dx.doi.org/10.3390/s18041087] [PMID: 29617319]

[70]
Anfossi L, Di Nardo F, Russo A, et al. Silver and gold nanoparticles as multi-chromatic lateral flow assay probes for the detection of food allergens. Anal Bioanal Chem  2019; 411(9): 1905-13.
 [http://dx.doi.org/10.1007/s00216-018-1451-6] [PMID: 30397760]

[71]
Ross GMS, Bremer MGEG, Nielen MWF. Consumer-friendly food allergen detection: Moving towards smartphone-based immunoassays. Anal Bioanal Chem  2018; 410(22): 5353-71.
 [http://dx.doi.org/10.1007/s00216-018-0989-7] [PMID: 29582120]

[72]
Patel N, Rocks BF, Bailey MP. A silver enhanced, gold labelled, immunosorbent assay for detecting antibodies to rubella virus. J Clin Pathol  1991; 44(4): 334-8.
 [http://dx.doi.org/10.1136/jcp.44.4.334] [PMID: 2030155]

[73]
Gomez F, Bogas G, Gonzalez M, et al. The clinical and immunological effects of Pru p 3 SLIT on peach and peanut allergy in patients with systemic reactions. Clin Exp Allergy  2017; 47(3): 339-50.
 [http://dx.doi.org/10.1111/cea.12901] [PMID: 28160513]

[74]
Gómez E, Fernández TD, Doña I, et al. Initial immunological changes as predictors for house dust mite immunotherapy response. Clin Exp Allergy  2015; 45(10): 1542-53.
 [http://dx.doi.org/10.1111/cea.12578] [PMID: 26032922]

[75]
Frischmeyer-Guerrerio PA, Keet CA, Guerrerio AL, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy. Clin Immunol  2014; 155(1): 47-59.
 [http://dx.doi.org/10.1016/j.clim.2014.08.006] [PMID: 25173802]

[76]
Palomares F, Ramos-Soriano J, Gomez F, et al. Pru p 3-glycodendropeptides based on mannoses promote changes in the immunological properties of dendritic and T-cells from LTPallergic patients. Mol Nutr Food Res  2019; 63(20): 1900553.
 [http://dx.doi.org/10.1002/mnfr.201900553] [PMID: 31368251]

[77]
Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: A systematic review and meta-analysis. Allergy  2017; 72(3): 342-65.
 [http://dx.doi.org/10.1111/all.13077] [PMID: 28120424]

[78]
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy  2017; 72(8): 1133-47.
 [http://dx.doi.org/10.1111/all.13124] [PMID: 28058751]

[79]
Pfaar O, Agache I, Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy  2019; 74(S108): 3-25.
 [http://dx.doi.org/10.1111/all.14077] [PMID: 31872476]

[80]
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy  2018; 73(4): 799-815.
 [http://dx.doi.org/10.1111/all.13319] [PMID: 29205393]

[81]
Rondón C, Blanca-López N, Campo P, et al. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo- controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy  2018; 73(4): 905-15.
 [http://dx.doi.org/10.1111/all.13350] [PMID: 29168570]

[82]
Pfaar O, Lou H, Zhang Y, Klimek L, Zhang L. Recent developments and highlights in allergen immunotherapy. Allergy  2018; 73(12): 2274-89.
 [http://dx.doi.org/10.1111/all.13652] [PMID: 30372537]

[83]
Reitsma S, Subramaniam S, Fokkens WWJ, Wang DY. Recent developments and highlights in rhinitis and allergen immunotherapy. Allergy  2018; 73(12): 2306-13.
 [http://dx.doi.org/10.1111/all.13617] [PMID: 30260494]

[84]
Chen M, Land M. The current state of food allergy therapeutics. Hum Vaccin Immunother  2017; 13(10): 2434-42.
 [http://dx.doi.org/10.1080/21645515.2017.1359363] [PMID: 28846472]

[85]
Gamazo C, D’Amelio C, Gastaminza G, Ferrer M, Irache JM. Adjuvants for allergy immunotherapeutics. Hum Vaccin Immunother  2017; 13(10): 2416-27.
 [http://dx.doi.org/10.1080/21645515.2017.1348447] [PMID: 28825867]

[86]
Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: Formulating future vaccines. J Clin Invest  2016; 126(3): 799-808.
 [http://dx.doi.org/10.1172/JCI81083] [PMID: 26928033]

[87]
Larsen SÃ¸T, Roursgaard M, Jensen KA, Nielsen GD. Nano titanium dioxide particles promote allergic sensitization and lung inflammation in mice. Basic Clin Pharmacol Toxicol  2010; 106(2): 114-7.
 [http://dx.doi.org/10.1111/j.1742-7843.2009.00473.x] [PMID: 19874288]

[88]
Sánchez-Navarro M, Rojo J. Targeting DC-SIGN with carbohydrate multivalent systems. Drug News Perspect  2010; 23(9): 557-72.
 [http://dx.doi.org/10.1358/dnp.2010.23.9.1437246] [PMID: 21152451]

[89]
Mascaraque A, Kowalczyk W, Fernández T, et al. Glycodendropeptides stimulate dendritic cell maturation and T cell proliferation: A potential influenza A virus immunotherapy. MedChemComm  2015; 6(10): 1755-60.
 [http://dx.doi.org/10.1039/C5MD00133A]

[90]
Le Guével X, Perez Perrino M, Fernández TD, et al. Multivalent glycosylation of fluorescent gold nanoclusters promotes increased human dendritic cell targeting via multiple endocytic pathways. ACS Appl Mater Interfaces  2015; 7(37): 20945-56.
 [http://dx.doi.org/10.1021/acsami.5b06541] [PMID: 26329370]

[91]
Shahbazi MA, Fernández TD, Mäkilä EM, et al. Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms. Biomaterials  2014; 35(33): 9224-35.
 [http://dx.doi.org/10.1016/j.biomaterials.2014.07.050] [PMID: 25123922]

[92]
Rodriguez MJ, Mascaraque A, Ramos-Soriano J, et al. Pru p 3-Epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy. Mol Nutr Food Res  2017; 61(10): 1700110.
 [http://dx.doi.org/10.1002/mnfr.201700110] [PMID: 28586170]

[93]
Souza J, Almeida LY, Luis MAV, et al. Mental health in the family health strategy as perceived by health professionals. Rev Bras Enferm  2017; 70(5): 935-41.
 [http://dx.doi.org/10.1590/0034-7167-2016-0492] [PMID: 28977218]

[94]
Gómez S, Gamazo C, Roman BS, Ferrer M, Sanz ML, Irache JM. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine  2007; 25(29): 5263-71.
 [http://dx.doi.org/10.1016/j.vaccine.2007.05.020] [PMID: 17576025]

[95]
Rose F, Wern JE, Gavins F, Andersen P, Follmann F, Foged C. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. J Control Release  2018; 271: 88-97.
 [http://dx.doi.org/10.1016/j.jconrel.2017.12.003] [PMID: 29217176]

[96]
Jeon JO, Kim S, Choi E, et al. Designed nanocage displaying ligand-specific Peptide bunches for high affinity and biological activity. ACS Nano  2013; 7(9): 7462-71.
 [http://dx.doi.org/10.1021/nn403184u] [PMID: 23927443]

[97]
Schöll I, Weissenböck A, Förster-Waldl E, et al. Allergen-loaded biodegradable poly(d,l-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy  2004; 34(2): 315-21.
 [http://dx.doi.org/10.1111/j.1365-2222.2004.01884.x] [PMID: 14987314]

[98]
Gamazo C, García-Azpíroz M, Souza RJD, Gastaminza G, Ferrer M, Irache JM. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis. Immunotherapy  2017; 9(15): 1205-17.
 [http://dx.doi.org/10.2217/imt-2017-0111] [PMID: 29130802]

[99]
Licciardi M, Montana G, Bondì ML, et al. An allergen-polymeric nanoaggregate as a new tool for allergy vaccination. Int J Pharm  2014; 465(1-2): 275-83.
 [http://dx.doi.org/10.1016/j.ijpharm.2014.01.031] [PMID: 24491528]

[100]
Hajavi J, Hashemi M, Sankian M. Evaluation of size and dose effects of rChe a 3 allergen loaded PLGA nanoparticles on modulation of Th2 immune responses by sublingual immunotherapy in mouse model of rhinitis allergic. Int J Pharm  2019; 563: 282-92.
 [http://dx.doi.org/10.1016/j.ijpharm.2019.03.040] [PMID: 30902708]

[101]
Balenga NAB, Zahedifard F, Weiss R, Sarbolouki MN, Thalhamer J, Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol  2006; 124(3): 602-14.
 [http://dx.doi.org/10.1016/j.jbiotec.2006.01.014] [PMID: 16515817]

[102]
Beilvert F, Tissot A, Langelot M, et al. DNA/amphiphilic block copolymer nanospheres reduce asthmatic response in a mouse model of allergic asthma. Hum Gene Ther  2012; 23(6): 597-608.
 [http://dx.doi.org/10.1089/hum.2012.024] [PMID: 22429072]

[103]
Pali-Schöll I, Szöllösi H, Starkl P, et al. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm  2013; 85(3) (3 Pt A): 656-64.
 [http://dx.doi.org/10.1016/j.ejpb.2013.03.003] [PMID: 23523543]

[104]
Taylor WA, Sheldon D, Spicer JW. Adjuvant and suppressive effects of Grass Conjuvac and other alginate conjugates on IgG and IgE antibody responses in mice. Immunology  1981; 44(1): 41-50.
 [PMID: 7275187]

[105]
Jatana S, Palmer BC, Phelan SJ, DeLouise LA. Immunomodulatory effects of nanoparticles on skin allergy. Sci Rep  2017; 7(1): 3979.
 [http://dx.doi.org/10.1038/s41598-017-03729-2] [PMID: 28638049]

[106]
Benedé S, Ramos-Soriano J, Palomares F, et al. Peptide glycodendrimers as potential vaccines for olive pollen allergy. Mol Pharm  2020; 17(3): 827-36.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.9b01082] [PMID: 31990560]

[107]
Rodriguez MJ, Ramos-Soriano J, Perkins JR, et al. Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model. Sci Rep  2019; 9(1): 4043.
 [http://dx.doi.org/10.1038/s41598-019-40114-7] [PMID: 30858392]

[108]
Roach KA, Stefaniak AB, Roberts JR. Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease. J Immunotoxicol  2019; 16(1): 87-124.
 [http://dx.doi.org/10.1080/1547691X.2019.1605553] [PMID: 31195861]

[109]
Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: Are we there yet? Int J Mol Sci  2020; 22(1): 385.
 [http://dx.doi.org/10.3390/ijms22010385] [PMID: 33396561]

[110]
Gatto F, Moglianetti M, Pompa P, Bardi G. Platinum nanoparticles decrease reactive oxygen species and modulate gene expression without alteration of immune responses in THP-1 monocytes. Nanomaterials  2018; 8(6): 392.
 [http://dx.doi.org/10.3390/nano8060392] [PMID: 29865145]

[111]
Albalawi F, Hussein MZ, Fakurazi S, Masarudin MJ. Engineered nanomaterials: The challenges and opportunities for nanomedicines. Int J Nanomedicine  2021; 16: 161-84.
 [http://dx.doi.org/10.2147/IJN.S288236] [PMID: 33447033]

[112]
Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: Size matters. J Nanobiotechnology  2014; 12(1): 5.
 [http://dx.doi.org/10.1186/1477-3155-12-5] [PMID: 24491160]

[113]
Zamboni WC, Szebeni J, Kozlov SV, Lucas AT, Piscitelli JA, Dobrovolskaia MA. Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations. Adv Drug Deliv Rev  2018; 136-137: 82-96.
 [http://dx.doi.org/10.1016/j.addr.2018.09.012] [PMID: 30273617]

[114]
Čapek J, Roušar T. Detection of oxidative stress induced by nanomaterials in cells-the roles of reactive oxygen species and glutathione. Molecules  2021; 26(16): 4710.
 [http://dx.doi.org/10.3390/molecules26164710] [PMID: 34443297]

[115]
Lehner R, Wang X, Marsch S, Hunziker P. Intelligent nanomaterials for medicine: Carrier platforms and targeting strategies in the context of clinical application. Nanomedicine  2013; 9(6): 742-57.
 [http://dx.doi.org/10.1016/j.nano.2013.01.012] [PMID: 23434677]

[116]
Klimek L, Schmidt-Weber CB, Kramer MF, Skinner MA, Heath MD. Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol  2017; 13(6): 599-610.
 [http://dx.doi.org/10.1080/1744666X.2017.1292133] [PMID: 28162007]

[117]
Weiss DS, Takeda K, Akira S, Zychlinsky A, Moreno E. MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus. Infect Immun  2005; 73(8): 5137-43.
 [http://dx.doi.org/10.1128/IAI.73.8.5137-5143.2005] [PMID: 16041030]

[118]
Shannahan JH, Brown JM. Engineered nanomaterial exposure and the risk of allergic disease. Curr Opin Allergy Clin Immunol  2014; 14(2): 95-9.
 [http://dx.doi.org/10.1097/ACI.0000000000000031] [PMID: 24378479]

[119]
Yoshioka Y, Kuroda E, Hirai T, Tsutsumi Y, Ishii KJ. Allergic responses induced by the immunomodulatory effects of nanomaterials upon skin exposure. Front Immunol  2017; 8: 169.
 [http://dx.doi.org/10.3389/fimmu.2017.00169] [PMID: 28261221]

[120]
Inoue K, Takano H, Yanagisawa R, Ichinose T, Sakurai M, Yoshikawa T. Effects of nano particles on cytokine expression in murine lung in the absence or presence of allergen. Arch Toxicol  2006; 80(9): 614-9.
 [http://dx.doi.org/10.1007/s00204-006-0075-3] [PMID: 16482471]

[121]
Bezemer GFG, Bauer SM, Oberdörster G, et al. Activation of pulmonary dendritic cells and Th2-type inflammatory responses on instillation of engineered, environmental diesel emission source or ambient air pollutant particles in vivo. J Innate Immun  2011; 3(2): 150-66.
 [http://dx.doi.org/10.1159/000321725] [PMID: 21099199]

[122]
Yanagisawa R, Takano H, Inoue K, et al. Titanium dioxide nanoparticles aggravate atopic dermatitis-like skin lesions in NC/Nga mice. Exp Biol Med  2009; 234(3): 314-22.
 [http://dx.doi.org/10.3181/0810-RM-304] [PMID: 19144875]

[123]
Hamad I, Moghimi SM. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opin Drug Deliv  2008; 5(2): 205-19.
 [http://dx.doi.org/10.1517/17425247.5.2.205] [PMID: 18248319]

[124]
Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Sci  2008; 320(5876): 674-7.
 [http://dx.doi.org/10.1126/science.1156995] [PMID: 18403674]

[125]
Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol  2017; 139(6): 1752-61.
 [http://dx.doi.org/10.1016/j.jaci.2017.04.010] [PMID: 28583447]

[126]
Ali S, Rytting E. Influences of nanomaterials on the barrier function of epithelial cells. Adv Exp Med Biol  2014; 811: 45-54.
 [http://dx.doi.org/10.1007/978-94-017-8739-0_3] [PMID: 24683026]

[127]
Dobrovolskaia MA. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. J Control Release  2015; 220(PtB): 571-83.
 [http://dx.doi.org/10.1016/j.jconrel.2015.08.056] [PMID: 26348388]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1381612829666230828104015	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286
Current Pharmaceutical Design

An Overview of Nanotechnological Approaches for the Diagnosis and Treatment of Allergic Illness

Abstract Play Pause

Related Journals

Related Books

Abstract
